Clinical Trial

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

Study acronym: PEACE1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2013-09-30; most recent amendment 2024-11-07.
Status change: Recruiting → Active, Not Recruiting 2019-01-24
Status change: Not Yet Recruiting → Recruiting 2015-03-18
Trial Details
NCT Number NCT01957436
Lead Sponsor UNICANCER
Collaborators: Janssen-Cilag Ltd., European Organisation for Research and Treatment of Cancer - EORTC, Ipsen, Sanofi
Conditions Metastatic Prostate Cancer
Enrollment 1,173 participants
Start Date 2013-11-13
Primary Completion 2021-08-18 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-12